Sylvie D Freeman

2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.

CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AM...

Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.

Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the U...

Behandeling Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and ...

FLAG-Ida plus GO bij AML: analyse

Augmented RIC versus standaard RIC voor allo-SCT bij AML: BMT CTN 0901

MRD en overleving bij AML: IPD meta-analyse

Beoordeling van minimale restziekte bij standaardrisico acute myeloïde leukemie